Literature DB >> 28546704

Feasibility of Axillary Reverse Mapping and Clinicopathological Features Predicting ARM Node Metastasis in Breast Cancer-a Pilot Study.

K Shiva Kumar1, G N Hemanth1, Poonam K Panjwani2, Suraj Manjunath1, Rakesh S Ramesh1, Rajaram Burrah1, Pritilata Rout2, D Ramu1, Elvis Peter Joseph1, Ravi Chandran1, C Prasad1, Vipin Goel1, Supari Divya2.   

Abstract

The axillary reverse mapping (ARM) technique has been described as an attempt to map and preserve the upper extremity lymphatic drainage during axillary lymph node dissection (ALND) and/or SLNB. This technique is based on the hypothesis that the lymphatic pathway from the upper extremity is not involved by metastasis from primary breast cancer. The ARM node/s however, has been found, in various studies, to be involved with metastatic foci in patients with extensive axillary lymph node metastases. Therefore, the oncological safety of this procedure has not yet been determined. In this pilot study, we assessed the ARM node intraoperatively for various parameters and compared it to final HPR, to try and determine the oncologic safety of preserving the ARM node. Seventy-two breast cancer patients were screened for this prospective pilot study which was planned to recruit 20 patients. The study was initiated on May 2014, 20 patients were recruited till July 2015. Eligibility criterion was as follows: patients requiring primary axillary lymph node dissection based on a clinically positive axilla. Forty-five patients were ineligible because they had either received neoadjuvant chemotherapy or underwent previous axillary surgery or axillary radiation (exclusion criteria). Seven patients refused to give consent. ARM node identification rate was 75%. The most common location of the ARM node was lateral to the latissimus dorsi pedicle (42.10%), none of them being malignant. None of the oval or firm nodes were malignant. Tumor deposits were identified in 13%. Fine-needle aspiration cytology (FNAC) had 100% specificity, 94.4% negative predictive value, 100% positive predictive value, and 50% sensitivity. ARM is feasible using blue dye alone, with an acceptable identification rate. Location, consistency, and intraoperative FNAC of the ARM node, put together, may be reliable parameters to predict involvement of the ARM node with metastasis.

Entities:  

Keywords:  Axillary reverse mapping; Sentinel node

Year:  2016        PMID: 28546704      PMCID: PMC5427024          DOI: 10.1007/s13193-016-0578-1

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  17 in total

1.  Morbidity of breast cancer patients following complete axillary dissection or sentinel node biopsy only: a comparative evaluation.

Authors:  Anton Haid; Roswitha Köberle-Wührer; Michael Knauer; Judit Burtscher; Heinz Fritzsche; William Peschina; Zerina Jasarevic; Maria Ammann; Klaus Hergan; Heinz Sturn; Gerhard Zimmermann
Journal:  Breast Cancer Res Treat       Date:  2002-05       Impact factor: 4.872

2.  Scientific Impact Award: Axillary reverse mapping (ARM) to identify and protect lymphatics draining the arm during axillary lymphadenectomy.

Authors:  Cristiano Boneti; Soheila Korourian; Zuleika Diaz; Carlos Santiago; Sheila Mumford; Laura Adkins; V Suzanne Klimberg
Journal:  Am J Surg       Date:  2009-10       Impact factor: 2.565

Review 3.  Lymphedema following axillary lymph node dissection for breast cancer.

Authors:  George H Sakorafas; George Peros; Luigi Cataliotti; George Vlastos
Journal:  Surg Oncol       Date:  2006-12-21       Impact factor: 3.279

4.  Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial.

Authors:  Robert E Mansel; Lesley Fallowfield; Mark Kissin; Amit Goyal; Robert G Newcombe; J Michael Dixon; Constantinos Yiangou; Kieran Horgan; Nigel Bundred; Ian Monypenny; David England; Mark Sibbering; Tholkifl I Abdullah; Lester Barr; Utheshtra Chetty; Dudley H Sinnett; Anne Fleissig; Dayalan Clarke; Peter J Ell
Journal:  J Natl Cancer Inst       Date:  2006-05-03       Impact factor: 13.506

5.  Axillary reverse mapping (ARM): a new concept to identify and enhance lymphatic preservation.

Authors:  Margaret Thompson; Soheila Korourian; Ronda Henry-Tillman; Laura Adkins; Sheilah Mumford; Kent C Westbrook; V Suzanne Klimberg
Journal:  Ann Surg Oncol       Date:  2007-05-04       Impact factor: 5.344

6.  Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer.

Authors:  D Kay Blanchard; John H Donohue; Carol Reynolds; Clive S Grant
Journal:  Arch Surg       Date:  2003-05

7.  Combined axillary reverse mapping (ARM) technique for breast cancer patients requiring axillary dissection.

Authors:  Claude Nos; Gabriel Kaufmann; Krishna B Clough; Marie-Anne Collignon; Eric Zerbib; Pino Cusumano; Fabrice Lecuru
Journal:  Ann Surg Oncol       Date:  2008-07-11       Impact factor: 5.344

8.  Extensive nodal disease may impair axillary reverse mapping in patients with breast cancer.

Authors:  Riccardo Ponzone; Nicoletta Tomasi Cont; Furio Maggiorotto; Elisa Cassina; Paola Mininanni; Nicoletta Biglia; Piero Sismondi
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

9.  Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial.

Authors:  Lee Gravatt Wilke; Linda M McCall; Katherine E Posther; Pat W Whitworth; Douglas S Reintgen; A Marilyn Leitch; Sheryl G A Gabram; Anthony Lucci; Charles E Cox; Kelly K Hunt; James E Herndon; Armando E Giuliano
Journal:  Ann Surg Oncol       Date:  2006-03-02       Impact factor: 5.344

10.  Evaluation of the metastatic status of lymph nodes identified using axillary reverse mapping in breast cancer patients.

Authors:  Katsumi Ikeda; Yoshinari Ogawa; Hisateru Komatsu; Yoshihiro Mori; Akira Ishikawa; Takayoshi Nakajima; Gou Oohira; Shinya Tokunaga; Hiroko Fukushima; Takeshi Inoue
Journal:  World J Surg Oncol       Date:  2012-11-01       Impact factor: 2.754

View more
  3 in total

1.  Application of Fluorescence Dye in Combination with Methylene Blue for Axillary Reverse Mapping in Patients with Modified Radical Mastectomy for Breast Cancer.

Authors:  Haiyi Wang; Baochao Wu; Zheng Wang
Journal:  J Oncol       Date:  2022-05-14       Impact factor: 4.501

2.  Prevention of lymphedema via axillary reverse mapping for arm lymph-node preservation following breast cancer surgery: a randomized controlled trial.

Authors:  Mohammed Faisal; Mohamed Gamal Sayed; Kerolos Antonious; Ahmmed Abo Bakr; Sherif Hussein Farag
Journal:  Patient Saf Surg       Date:  2019-11-14

3.  Clinical application of axillary reverse mapping in patients with breast cancer: A systematic review and meta-analysis.

Authors:  Wilson A Wijaya; Jing Peng; Yinhai He; Junjie Chen; Ying Cen
Journal:  Breast       Date:  2020-08-18       Impact factor: 4.380

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.